Literature DB >> 576555

Effects on rat urinary kallikrein excretion of bumetanide, bendroflumethiazide and hydralazine.

K Nielsen, E Arrigoni-Martelli.   

Abstract

Single and/or repeated administrations of bumetanide, bendroflumethiazide and hydralazine to normotensive and spontaneously hypertensive rats resulted in an increase of urinary kallikrein excretion. No correlation was found with sodium output. The role of the increased plasma renin activity is discussed and it is suggested that the activation of the renal kallikrein-kinin system is related to the increase in renal blood flow.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 576555     DOI: 10.1111/j.1600-0773.1977.tb02077.x

Source DB:  PubMed          Journal:  Acta Pharmacol Toxicol (Copenh)        ISSN: 0001-6683


  7 in total

1.  Relationship between kallikrein and PRA after intravenous furosemide.

Authors:  G A Cinotti; G Stirati; F Taggi; R Ronci; B M Simonetti; A Pierucci
Journal:  J Endocrinol Invest       Date:  1979 Apr-Jun       Impact factor: 4.256

2.  The renal kallikrein-kinin system in spontaneously hypertensive rats.

Authors:  G Bönner; T Unger; W Rascher; G Speck; D Ganten; F Gross
Journal:  Agents Actions       Date:  1984-10

Review 3.  The renal kallikrein-kinin system in human and in experimental hypertension.

Authors:  O A Carretero; A G Scicli
Journal:  Klin Wochenschr       Date:  1978

4.  Short lasting increase in urinary specific kallikrein activity during long term administration of furosemide.

Authors:  J L Bascands; J P Girolami; C Pecher; G Cabos; J P Moatti; J M Suc; Y Manuel
Journal:  Agents Actions       Date:  1987-12

5.  Interactions of diuretics with the renal kallikrein-kinin and prostaglandin systems.

Authors:  A Overlack; K O Stumpe; H M Müller; R Kolloch; M Higuchi
Journal:  Klin Wochenschr       Date:  1982-10-01

Review 6.  [Renal kallikrein-kinin system and control of blood pressure (author's transl)].

Authors:  A Distler; H P Wolff
Journal:  Klin Wochenschr       Date:  1979-10-01

Review 7.  Bumetanide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use.

Authors:  A Ward; R C Heel
Journal:  Drugs       Date:  1984-11       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.